Neonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) CEO Thomas Chen purchased 5,556 shares of Neonc Technologies stock in a transaction on Friday, September 11th. The stock was bought at an average cost of $3.60 per share, with a total value of $20,001.60. Following the transaction, the chief executive officer directly owned 19,261 shares of the company’s stock, valued at approximately $69,339.60. The trade was a 40.54% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
Neonc Technologies Price Performance
Shares of NTHI stock opened at $3.41 on Friday. The stock’s 50 day simple moving average is $3.98 and its 200 day simple moving average is $5.18. Neonc Technologies Holdings, Inc. has a twelve month low of $2.95 and a twelve month high of $12.99.
Neonc Technologies (NASDAQ:NTHI – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.46).
Analyst Ratings Changes
View Our Latest Stock Analysis on NTHI
Institutional Investors Weigh In On Neonc Technologies
A number of institutional investors have recently added to or reduced their stakes in NTHI. Westmount Partners LLC raised its holdings in Neonc Technologies by 355.2% in the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after acquiring an additional 153,858 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Neonc Technologies during the 2nd quarter worth approximately $815,000. Bank of America Corp DE bought a new stake in shares of Neonc Technologies during the second quarter valued at approximately $1,017,000. Finally, Global Retirement Partners LLC bought a new stake in shares of Neonc Technologies during the second quarter valued at approximately $126,000.
Neonc Technologies Company Profile
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
See Also
- Five stocks we like better than Neonc Technologies
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Neonc Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neonc Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
